Ipsen is paying €200 million ($227 million) upfront for Memo Therapeutics, with milestones pushing the total to over €700 million, or roughly $796 million. Memo is privately held, so there’s no public share price to premium against, no unaffected trading level to measure the deal against. That’s the tell: this is a binary bet on one asset, not a market-cap arbitrage play.
What Ipsen actually gets is potravitug, a Phase 2 monoclonal antibody against BK polyomavirus, the kidney-transplant complication with zero approved treatments. The Fast Track and Orphan Drug designations buy Ipsen a faster regulatory runway, and a pivotal Phase 2/3 study is slated to start later this year. Memo keeps its other assets and staff, spinning them into a new entity called Memorises Bio. Clean carve-out, no dead weight.
This is Ipsen’s second buyout in three days. Monday it agreed to pay $450 million upfront, up to $1.75 billion total, for Kartos Therapeutics and its MDM2 blocker for myelofibrosis. Two deals, two therapeutic areas, same playbook: pay modest cash up front, back-load the real money into milestones the seller has to earn. Ipsen isn’t writing a blank check, it’s renting optionality on Phase 2 and Phase 3 data it hasn’t seen yet.
The math only works if potravitug clears its pivotal trial. Miss that, and Ipsen’s out $227 million for a molecule with no approved comparator to benchmark against. Both deals are expected to close in Q3 2026.
Diana Kowalski